跳至主要内容
临床试验/NCT01059539
NCT01059539已完成3 期

A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder

Forest Laboratories35 个研究点 分布在 4 个国家目标入组 403 人开始时间: 2010年2月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
403
试验地点
35
主要终点
Change From Baseline in the YMRS Total Score at Week 16

研究概览

简要总结

The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with bipolar I disorder.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who have provided informed consent prior to any study specific procedures.
  • Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID).
  • Patients who experienced a manic or mixed episode that required treatment within the past 12 months.
  • Patients with normal physical examination, laboratory, vital signs, and electrocardiogram (ECG).

排除标准

  • Patients with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I disorder.

研究组 & 干预措施

Cariprazine 3-12 mg/day for 16 weeks

Experimental

Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator.

干预措施: Cariprazine (Drug)

结局指标

主要结局

Change From Baseline in the YMRS Total Score at Week 16

时间窗: Baseline to Week 16

The Young Mania Rating Scale (YMRS) is an 11-item scale that assesses manic symptoms based on the patient's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11 items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of each item is rated on a 5-point (0-4) or a 9-point (0-8) scale. The total score of all 11 items can range from 0 to 60. A higher score indicates worse manic symptoms. A negative change score indicates improvement.

次要结局

  • Change From Baseline in the MADRS Total Score at Week 16(Baseline to Week 16)

研究者

发起方
Forest Laboratories
申办方类型
Industry
责任方
Sponsor

研究点 (35)

Loading locations...

相似试验

Long-term Safety and Tolerability of Cariprazine for... | 临床试验